Phoenix Biotech Acquisition Corp.
PBAX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | 0.00 | -9.01 | 0.00 |
| FCF Yield | -1.99% | -0.16% | -0.10% |
| EV / EBITDA | -17.83 | -120.71 | -2,054.43 |
| Quality | |||
| ROIC | 5,076.74% | -0.02% | -0.18% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 1.64 | 2.21 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -56.68% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.11 | -0.03 | 3.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |